Viking Obesity Pill Faces Steep Climb Against Lilly’s Tirzepatide, Analyst Calls Downtrend Reaction ‘Extreme’

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock’s sell-off is excessive.

Latest Ratings for VKTX

DateFirmActionFromTo Feb 2022Raymond JamesMaintainsOutperform Jul 2021Raymond JamesMaintainsOutperform May 2021Raymond JamesDowngradesStrong BuyOutperform

View More Analyst Ratings for VKTX

View the Latest Analyst Ratings

read more